# Clinical Trials Data EGFR - Document 56

# Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01394120

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologic diagnosis of pancreas adenocarcinoma\n\* Clinical stage IV\n\* Feasible patient for chemotherapy\n\* Availability of tumor tissue or possibility of a tumor biopsy to define therapeutic targets\n\* Informed written consent\n\nExclusion Criteria:\n\n\* Previous systemic treatment for advanced pancreas adenocarcinoma\n\* Contraindication to the administration of any of the drugs used in the study: capecitabine, 5Fluouracil, irinotecan, oxaliplatin, gemcitabine or erlotinib",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the clinical trial information provided, a patient with an EGFR gene mutation would be eligible for the trial as there is no specific exclusion related to EGFR mutations. The inclusion and exclusion criteria do not mention EGFR gene mutations as a determining factor for eligibility.  
  
Here is a breakdown of the criteria:  
  
- \*\*Inclusion Criteria\*\*: The patient must have a histologic diagnosis of pancreas adenocarcinoma, be in clinical stage IV, be feasible for chemotherapy, and have available tumor tissue or the possibility of a tumor biopsy. Additionally, the patient must provide informed written consent.  
  
- \*\*Exclusion Criteria\*\*: The patient must not have received previous systemic treatment for advanced pancreas adenocarcinoma or have a contraindication to any drugs used in the study (capecitabine, 5Fluorouracil, irinotecan, oxaliplatin, gemcitabine, or erlotinib).  
  
Assuming the patient with the EGFR gene mutation meets all the inclusion criteria and does not fall under any exclusion criteria, they would be eligible to participate in the clinical trial.